Genmab A/S

Forecast & Rating11 analysts currently cover Genmab A/S, with about 90.9% giving a positive rating — meaning they expect the stock to rise. The average price target is $37.96, about 31.5% upside from the current price of $28.87. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 55.4% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Genmab A/S closely still see room for the stock to rise. Data as of Jul 22, 2026; for reference only and not investment advice.